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CORRESPONDENCE
Re: Population-Based
Case–Control Study of HER2
Genetic Polymorphism and
Breast Cancer Risk
Human epidermal growth factor re-
ceptor 2 (HER2) is a proto-oncogene en-
coding a transmembrane glycoprotein
with tyrosine kinase activity. The ampli-
fication and overexpression of this gene
have been observed in breast and ovar-
ian cancers and are associated with the
response of breast cancers to chemo-
therapy. A single nucleotide polymor-
phism (SNP) at codon 655 resulting in a
valine to isoleucine change (Val655Ile)
was reported in the Journal (1) to be
associated with an increased risk of
breast cancer among women in Shang-
hai, China. The frequency of the valine
allele varies among ethnic groups. The
valine allele has a frequency of 20% in
Caucasians and 24% in African-Ameri-
cans but was not detected in an African
population (2). Studies among British
(3) and German–Caucasian (4) popula-
tions showed that the valine allele was
not associated with a higher risk for
breast or ovarian cancer.
Because genetic heterogeneity exists
among individuals from different geo-
graphical regions of China (5,6), we in-
vestigated the frequency of the Val655Ile
HER2 polymorphism in a southern
Chinese-based age-matched case–
control study in Hong Kong to deter-
mine whether it is associated with risk
for ovarian cancer in this population.
Paraffin-embedded tissue blocks
were retrieved from the files of the De-
partment of Pathology, Queen Mary
Hospital, a major referral center in Hong
Kong for patients with gynecologic ma-
lignancies. Nontumor blocks were ob-
tained from 205 Chinese women diag-
nosed with primary epithelial ovarian
carcinoma and from 205 age-matched
control subjects. Control subjects had
undergone total hysterectomy for a be-
nign condition and did not have ovarian
cancer. The mean age of both groups
was 50 years. The Val655Ile polymor-
phism was detected by restriction frag-
ment length polymorphism as described
(1) except that the primers were 5-
ATCCCTGACCCTGGCTTCC-3 (for-
ward) and 5-CGCTTGATGAGGATC-
CCAAA-3 (reverse). Statistical analysis
was performed with a two-sided 2 test
to compare the allele and genotype fre-
quencies in the studied sample with
those reported in ethnic control popula-
tions.
We did not detect a valine/valine ho-
mozygote among the 410 subjects stud-
ied. The valine allele frequency found in
normal control subjects was similar to
that reported in the Shanghai population
(1) but was statistically significantly dif-
ferent (P<.001) from those in other eth-
nic group studies (2–4). Both the valine
allele frequency and the genotype fre-
quency were statistically significantly
different between patients with ovarian
cancer and normal control subjects
(P  .022 and .016, respectively). The
genotypes were in Hardy–Weinberg
equilibrium in both cancer and control
groups. Heterozygote valine allele carri-
ers had a statistically significantly de-
creased risk for ovarian cancer com-
pared with homozygote isoleucine allele
carriers (2  5.831; 1 df; P  .016;
odds ratio  0.517, 95% confidence in-
terval  0.310 to 0.865). These results
differ from those for breast cancer re-
ported by Xie et al. (1) and those in a
British population in which the valine
allele was not associated with breast or
ovarian cancer risk (3) (Table 1).
We suggest that the risk for ovarian
cancer of women in the southern Chi-
nese population of Hong Kong who
have the valine allele is lower than the
risk of those without the valine allele.
We note that an SNP in the RAD51 gene
was also associated with a lower risk for
ovarian cancer among BRCA1 and/or
BRCA2 mutation carriers (7). Our re-
sults need to be verified in a larger
study, and the odds ratio for ovarian
cancer among valine/valine homozy-
gotes needs to be determined. It is pos-
sible that HER2 is in linkage disequilib-
Table 1. Summary of genotyping result for HER2 valine-655→isoleucine (Val655Ile) polymorphism in different ethnic groups
Population Subjects*
No. of
subjects
Genotype frequency, %
Val allele
frequency, % P valueVal/Val Val/Ile Ile/Ile
Hong Kong Chinese [this study] Control 205 0 23.4 76.6 11.7
OvCa 205 0 13.7 86.3 6.8 .022†
Shanghai Chinese [Xie et al. (1)] Control 361 0.3 21.7 78.0 11.1
BrCa 339 3.2 25.1 71.7 15.8 .011†
.005‡
British [Baxter and Campbell (3)] Control 256 6.6 39.4 53.9 26.4
BrCa 315 5.1 34.6 60.3 22.4 .13†
.13‡
OvCa 314 7.6 34.1 58.3 24.7 .56†
.31‡
German-Caucasian [Wang-Gohrke] and Chang-Claude (4) Control 1078 5 35 60 23
BrCa 615 6 36 69 24 .56†
.83‡
Ghanaian [Ameyaw et al. (2)] Total 200 0 0 100 0
African-American [Ameyaw et al. (2)] Total 90 4.4 38.9 56.7 24
Caucasian [Ameyaw et al. (2)] Total 257 5.4 29.2 65.4 20
*OvCa  ovarian cancer; BrCa  breast cancer.
†P values are from the two-sided 2 test for comparison between Val allele frequency and Ile allele frequency.
‡P values represent the genotype frequencies as reported by previous authors.
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rium with other candidate genes nearby
on the same chromosome that are also
associated with the risk for ovarian can-
cer. Consequently, the usefulness of the
Val655Ile polymorphism for determin-
ing the risk for breast and/or ovarian
cancer and its response to treatment may
be limited.
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